BridgeBio Pharma Inc (BBIO) — Long-term Investment Intensity
BridgeBio Pharma Inc (BBIO) has a Long-term Investment Intensity of 9.2% as of September 2025. Long-term investments of $92.17 Million represent 9.2% of total assets of $998.25 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check BridgeBio Pharma Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
BridgeBio Pharma Inc Long-term Investment Intensity (2018–2024)
This chart shows how BridgeBio Pharma Inc's Long-term Investment Intensity has evolved across 5 annual periods from 2018 to 2024. As of September 2025, the intensity stands at 9.2%, reflecting long-term investments of $92.17 Million against total assets of $998.25 Million USD. Explore BBIO debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for BridgeBio Pharma Inc (2018–2024)
The table below presents the year-by-year Long-term Investment Intensity for BridgeBio Pharma Inc from 2018 to 2024, covering 5 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see BBIO stock market capitalisation.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 15.6% | $143.75 Million | $919.34 Million | ▲ +8.6 pp |
| 2022 | 7.0% | $43.65 Million | $623.04 Million | ▲ +2.2 pp |
| 2021 | 4.9% | $49.15 Million | $1.01 Billion | ▼ -0.1 pp |
| 2019 | 4.9% | $31.14 Million | $631.68 Million | ▲ +1.3 pp |
| 2018 | 3.7% | $17.05 Million | $464.94 Million | — |